European Medicines Agency Will Review Marketing Application for Niraparib to Treat Ovarian Cancer

European Medicines Agency Will Review Marketing Application for Niraparib to Treat Ovarian Cancer
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of niraparib for the treatment of platinum-sensitive ovarian cancer patients, according to Tesaro, the product manufacturer. “Tesaro is committed to improving the lives of patients with cancer by responsible development and commercialization, and the validation of the niraparib MAA represents a

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *